Stifel Reiterates Buy on Mirum Pharmaceuticals, Maintains $48 Price Target
Portfolio Pulse from Benzinga Newsdesk
Stifel analyst Dae Gon Ha has reiterated a Buy rating on Mirum Pharmaceuticals (NASDAQ:MIRM) and maintained a $48 price target.
June 17, 2024 | 4:07 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Stifel analyst Dae Gon Ha has reiterated a Buy rating on Mirum Pharmaceuticals and maintained a $48 price target.
The reiteration of a Buy rating and the maintenance of a $48 price target by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100